Download presentation
Presentation is loading. Please wait.
Published byAubrey Parks Modified over 5 years ago
1
Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review
Amy S. Levin, MD, Iris M. Otani, MD, Timothy Lax, MD, Ephraim Hochberg, MD, Aleena Banerji, MD The Journal of Allergy and Clinical Immunology: In Practice Volume 5, Issue 1, Pages e1 (January 2017) DOI: /j.jaip Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Figure 1 Modified National Cancer Institute Common Terminology Criteria for Adverse Events Scale. From National Cancer Institute.13 The Journal of Allergy and Clinical Immunology: In Practice 2017 5, e1DOI: ( /j.jaip ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
3
Figure 2 Rituximab same-day rechallenge—Grading and outcome. *Rechallenge at our institution is 50% standard infusion rate. †Among these patients, 2 had grade 1B, 4 had grade 2, 1 had grade 4 reactions. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, e1DOI: ( /j.jaip ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
4
Figure 3 Evaluation of patients referred to allergy. Desens, Desensitization. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, e1DOI: ( /j.jaip ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
5
Figure E1 Massachusetts General Hospital Rituximab Desensitization Protocol. The Journal of Allergy and Clinical Immunology: In Practice 2017 5, e1DOI: ( /j.jaip ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.